Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Gastric Cancer | Research

Nomogram to predict overall survival of patients receiving radical gastrectomy and incomplete peri-operative adjuvant chemotherapy for stage II/III gastric cancer: a retrospective bi-center cohort study

Authors: Dian Liu, Hu Quan, Min Ma, Huijun Zhou, Xiaolin Yang, Zhengchun Wu, Jia Luo, Hua Xiao, Yanping Xiao

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

To establish a nomogram to predict the probability of survival of patients with stage II/III gastric cancer (GC) who received incomplete peri-operative adjuvant chemotherapy (PAC).

Methods

The medical records of stage II/III GC patients who received curative resection and 1 to 5 cycles of PAC from two tertiary hospitals were retrospectively reviewed. Patients were randomly classified into either a training group or validation group at a ratio of 7:3. The nomogram was constructed based on various prognostic factors using Cox regression analysis in the training cohort, and was validated by the validation group. Concordance index and calibration curves were used to evaluate the discrimination and calibration of the nomogram. Additionally, decision curve analysis (DCA) was used to compare the net clinical benefits of the nomogram and eighth version of TNM staging system.

Results

A total of 1,070 consecutive patients were included and 749 patients were enrolled into the training group. Lower body mass index (< 18.5 kg/m2), total gastrectomy, stage III disease and fewer cycles of PAC were identified to be independent predictors for poorer survival. The area under the curve (AUC) values of receiver operating characteristics (ROC) curve predicting 5-year survival probabilities and C-index were 0.768 and 0.742, 0.700 (95%CI: 0.674–0.726) and 0.689 (95%CI: 0.646–0.732) in the training and validation groups, respectively. The calibration curves in the validation cohort showed good agreement between the prediction and observation of 1-, 3- and 5-year survival probabilities. Furthermore, DCA showed that our model has a better net benefit than that of TNM staging system.

Conclusions

The findings emphasize the value of completing PAC. The nomogram which was established to predict survival probability in patients with stage II/III GC receiving radical gastrectomy and incomplete PAC had good accuracy and was verified through both internal and external validation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
go back to reference Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMed Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMed
3.
go back to reference Ajani JA, D’Amico TA, Almhanna K, et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(10):1286–312.CrossRefPubMed Ajani JA, D’Amico TA, Almhanna K, et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(10):1286–312.CrossRefPubMed
4.
go back to reference Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21.CrossRef
5.
go back to reference Tsuburaya A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014;15(8):886–93.CrossRefPubMed Tsuburaya A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014;15(8):886–93.CrossRefPubMed
6.
go back to reference Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616–28.CrossRefPubMed Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616–28.CrossRefPubMed
7.
go back to reference Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.CrossRefPubMed Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.CrossRefPubMed
8.
go back to reference Liu X, Wu Z, Lin E, et al. Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy. Clin Nutr. 2019;38(4):1853–60.CrossRefPubMed Liu X, Wu Z, Lin E, et al. Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy. Clin Nutr. 2019;38(4):1853–60.CrossRefPubMed
9.
go back to reference Lu J, Xu BB, Zheng CH, et al. Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric cancer: an international multicenter study. Front Oncol. 2020;10:574611.CrossRefPubMedPubMedCentral Lu J, Xu BB, Zheng CH, et al. Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric cancer: an international multicenter study. Front Oncol. 2020;10:574611.CrossRefPubMedPubMedCentral
10.
go back to reference Park KB, Jun KH, Song KY, et al. Development of a staging system and survival prediction model for advanced gastric cancer patients without adjuvant treatment after curative gastrectomy: a retrospective multicenter cohort study. Int J Surg. 2022;101:106629.CrossRefPubMed Park KB, Jun KH, Song KY, et al. Development of a staging system and survival prediction model for advanced gastric cancer patients without adjuvant treatment after curative gastrectomy: a retrospective multicenter cohort study. Int J Surg. 2022;101:106629.CrossRefPubMed
11.
go back to reference Ma L, Chen G, Wang D, et al. A nomogram to predict survival probability of gastric cancer patients undergoing radical surgery and adjuvant chemotherapy. Front Oncol. 2022;12:893998.CrossRefPubMedPubMedCentral Ma L, Chen G, Wang D, et al. A nomogram to predict survival probability of gastric cancer patients undergoing radical surgery and adjuvant chemotherapy. Front Oncol. 2022;12:893998.CrossRefPubMedPubMedCentral
12.
go back to reference Morris M, Platell C, Fritschi L, lacopetta B. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer. 2007;96(5):701–7.CrossRefPubMedPubMedCentral Morris M, Platell C, Fritschi L, lacopetta B. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer. 2007;96(5):701–7.CrossRefPubMedPubMedCentral
13.
go back to reference Matsumoto I, Tanaka M, Shirakawa S, et al. Postoperative serum albumin level is a marker of incomplete adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2015;22(7):2408–24.CrossRefPubMed Matsumoto I, Tanaka M, Shirakawa S, et al. Postoperative serum albumin level is a marker of incomplete adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2015;22(7):2408–24.CrossRefPubMed
14.
go back to reference Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.CrossRefPubMed Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.CrossRefPubMed
15.
go back to reference Xiao H, Zhou H, Zhang P, et al. Association among the prognostic nutritional index, completion of adjuvant chemotherapy, and cancer-specific survival after curative resection of stage II/III gastric cancer. Eur J Clin Nutr. 2020;74(4):555–64.CrossRefPubMed Xiao H, Zhou H, Zhang P, et al. Association among the prognostic nutritional index, completion of adjuvant chemotherapy, and cancer-specific survival after curative resection of stage II/III gastric cancer. Eur J Clin Nutr. 2020;74(4):555–64.CrossRefPubMed
16.
go back to reference Peng W, Dai J, Liu CC, et al. Body mass index and prognosis of patients with stage II/III gastric cancer after curative gastrectomy: completion of perioperative adjuvant chemotherapy may be a confounding factor. Front Oncol. 2022;12:899677.CrossRefPubMedPubMedCentral Peng W, Dai J, Liu CC, et al. Body mass index and prognosis of patients with stage II/III gastric cancer after curative gastrectomy: completion of perioperative adjuvant chemotherapy may be a confounding factor. Front Oncol. 2022;12:899677.CrossRefPubMedPubMedCentral
17.
go back to reference Xiao H, Xiao Y, Chen P, et al. Association among blood transfusion, postoperative infectious complications, and cancer-specific survival in patients with stage II/III gastric cancer after radical gastrectomy: emphasizing benefit from adjuvant chemotherapy. Ann Surg Oncol. 2021;28(4):2394–404.CrossRefPubMed Xiao H, Xiao Y, Chen P, et al. Association among blood transfusion, postoperative infectious complications, and cancer-specific survival in patients with stage II/III gastric cancer after radical gastrectomy: emphasizing benefit from adjuvant chemotherapy. Ann Surg Oncol. 2021;28(4):2394–404.CrossRefPubMed
18.
go back to reference Lu J, Zheng CH, Cao LL, et al. The effectiveness of the 8th American Joint Committee on Cancer TNM classification in the prognosis evaluation of gastric cancer patients: a comparative study between the 7th and 8th editions. Eur J Surg Oncol. 2017;43(12):2349–56.CrossRefPubMed Lu J, Zheng CH, Cao LL, et al. The effectiveness of the 8th American Joint Committee on Cancer TNM classification in the prognosis evaluation of gastric cancer patients: a comparative study between the 7th and 8th editions. Eur J Surg Oncol. 2017;43(12):2349–56.CrossRefPubMed
19.
go back to reference Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081–92.CrossRefPubMed Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081–92.CrossRefPubMed
20.
go back to reference Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed
21.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral
22.
go back to reference Kanda M, Murotani K, Kobayashi D, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery. 2015c;158(6):1573–80.CrossRefPubMed Kanda M, Murotani K, Kobayashi D, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery. 2015c;158(6):1573–80.CrossRefPubMed
23.
go back to reference Hosoda K, Ushiku H, Katada C, et al. Preoperative chemotherapy could modify recurrence patterns through postoperative complications in patients with gastric cancer. Langenbecks Arch Surg. 2021;406(4):1045–55.CrossRefPubMed Hosoda K, Ushiku H, Katada C, et al. Preoperative chemotherapy could modify recurrence patterns through postoperative complications in patients with gastric cancer. Langenbecks Arch Surg. 2021;406(4):1045–55.CrossRefPubMed
24.
go back to reference Aoyama T, Yoshikawa T, Shirai J, et al. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2013;20(6):2000–6.CrossRefPubMed Aoyama T, Yoshikawa T, Shirai J, et al. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2013;20(6):2000–6.CrossRefPubMed
25.
go back to reference Yamashita K, Kurokawa Y, Yamamoto K, et al. Risk factors for poor compliance with adjuvant S-1 chemotherapy for gastric cancer: a multicenter retrospective study. Ann Surg Oncol. 2017;24(9):2639–45.CrossRefPubMed Yamashita K, Kurokawa Y, Yamamoto K, et al. Risk factors for poor compliance with adjuvant S-1 chemotherapy for gastric cancer: a multicenter retrospective study. Ann Surg Oncol. 2017;24(9):2639–45.CrossRefPubMed
26.
go back to reference Jang SH, Jung YJ, Kim MG, Kwon SJ. The prognostic significance of compliance with postoperative adjuvant chemotherapy in patients with stage III gastric cancer: an observational study. J Gastric Cancer. 2018;18(1):48–57.CrossRefPubMedPubMedCentral Jang SH, Jung YJ, Kim MG, Kwon SJ. The prognostic significance of compliance with postoperative adjuvant chemotherapy in patients with stage III gastric cancer: an observational study. J Gastric Cancer. 2018;18(1):48–57.CrossRefPubMedPubMedCentral
27.
go back to reference Aoyama T, Kawabe T, Fujikawa H, et al. Loss of lean body mass as an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2015;22(8):2560–6.CrossRefPubMed Aoyama T, Kawabe T, Fujikawa H, et al. Loss of lean body mass as an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2015;22(8):2560–6.CrossRefPubMed
28.
go back to reference Seo SH, Kim SE, Kang YK, et al. Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. BMC Cancer. 2016;16(1):900.CrossRefPubMedPubMedCentral Seo SH, Kim SE, Kang YK, et al. Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. BMC Cancer. 2016;16(1):900.CrossRefPubMedPubMedCentral
29.
go back to reference Meng Q, Tan S, Jiang Y, et al. Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: a randomized clinical trial. Clin Nutr. 2021;40(1):40–6.CrossRefPubMed Meng Q, Tan S, Jiang Y, et al. Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: a randomized clinical trial. Clin Nutr. 2021;40(1):40–6.CrossRefPubMed
30.
go back to reference Li SS, Udelsman BV, Parikh A, Klempner SJ, Clark JW, Roeland EJ, et al. Impact of postoperative complication and completion of multimodality therapy on survival in patients undergoing gastrectomy for advanced gastric cancer. J Am Coll Surg. 2020;230(6):912–24.CrossRefPubMed Li SS, Udelsman BV, Parikh A, Klempner SJ, Clark JW, Roeland EJ, et al. Impact of postoperative complication and completion of multimodality therapy on survival in patients undergoing gastrectomy for advanced gastric cancer. J Am Coll Surg. 2020;230(6):912–24.CrossRefPubMed
Metadata
Title
Nomogram to predict overall survival of patients receiving radical gastrectomy and incomplete peri-operative adjuvant chemotherapy for stage II/III gastric cancer: a retrospective bi-center cohort study
Authors
Dian Liu
Hu Quan
Min Ma
Huijun Zhou
Xiaolin Yang
Zhengchun Wu
Jia Luo
Hua Xiao
Yanping Xiao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12103-1

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine